Wim, you may be right. we do know the tests will be expensive.
That being said, we know based on the PR they are evaluating partners rather than just one. while the amounts being debated may just be profit sharing and milestone payments, it could also be up front payment as the final deciding factor.
I can see a company willing to spend 30 million on the drug. 20 million for tests and 10 million up front. Its a 2 billion dollar a year market. Especially if they can get a 60% split of the profit.
I have seen drugs where they give 30 million for just the license to be able to able to use the technology exclusively.
And I am just throwing out possible numbers. they may cost 15 million for the tests and they get 5 million for up front for a 20 million initial investment.
I just feel its a possible outcome and one Odidi would be exploring as that kind of cash would get us through the year end until he can get Rexista refiled and partnered.
My thought is with the last offering giving away 30% of the company for 5 million he will not want to dilute much further. I could even see him relent on the % of profit sharing in order to get upfront cash. at this point, I would suspect he is in survival mode for the company to get through the Rexista approval. They certainly can not count on Generics now so he should be thinking of some other option.
who knows, maybe he will be smart enough to license out Podras as soon as that is proved in Humans. He could easily start licensing that out for other companies to use as an NDA-S for already marketed drugs and get it to market sooner. than to just try and make his own drugs and start from square 1 with an NDA then also need to partner it.
AI
Market Data 
Markets 
